Beckman Coulter, Inc. Enters into A Series of Related Agreements with Quidel Corporation and A Subsidiary Thereof
July 26, 2021 at 08:37 am EDT
Share
Danaher Corporation’s Beckman Coulter Inc. entered into a series of related agreements with Quidel Corporation and a subsidiary thereof (“Quidel”) pursuant to which, among other matters, Quidel’s business of selling and distributing the BNP test for the Beckman Coulter Access family of immunoassay systems will be transitioned to Beckman Coulter, modifying and partially terminating the parties’ prior commercial arrangement. As part of the modification and termination of the prior arrangement, Beckman Coulter has acquired the exclusive right to manufacture, distribute, and sell the BNP assay currently sold as TRIAGE BNP by Quidel, which will be re-branded as Access BNP. The agreements also resolve litigation that Beckman Coulter initiated against Quidel related to the prior commercial arrangement. As consideration under the agreements, the Company will pay Quidel a per-test fee for each BNP assay test sold from the date of the initial commercial transition in 2021 through 2029, with a minimum annual fee of $70 million and a maximum annual fee of $75 million (subject to proration in 2021). The Company will record a pre-tax charge of approximately $550 million ($418 million after-tax) in the third quarter of 2021 related to the modification and termination of the prior commercial arrangement and resolution of the litigation related to these agreements.
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
QUIDELORTHO CORPORATION 
